NCT02635243View on ClinicalTrials.gov

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

SAR438544

"Pharmaceutical form:solution~Route of administration: subcutaneous"

DRUG

r-glucagon

"Pharmaceutical form:solution~Route of administration: subcutaneous"

DRUG

insulin

"Pharmaceutical form:solution~Route of administration: intravenous"

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT02635243 - A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia | Biotech Hunter | Biotech Hunter